-
公开(公告)号：US11807693B2
公开(公告)日：2023-11-07
申请号：US17160819
申请日：2021-01-28
Applicant: AMGEN INC.
Inventor： Jerry Ryan Holder , Gayathri Swaminath , Michael J. Frohn , Brian Alan Lanman , Anthony B. Reed , Leslie P. Miranda , John Gordon Allen , Alexander J. Pickrell , Aaron C. Siegmund , Lewis D. Pennington , Bryant Yang
CPC classification number: C07K7/08 , A61K38/10 , A61K47/542 , A61K47/60 , C07K14/47 , A61K38/00 , C07K2319/30
Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
-
公开(公告)号：US09328134B2
公开(公告)日：2016-05-03
申请号：US14767737
申请日：2014-02-20
Applicant: AMGEN INC.
Inventor： John Gordon Allen , Christopher H. Fotsch , Michael J. Frohn , John Douglas McCarter , Mirna Mujacic , Alexander J. Pickrell
IPC: C07D309/10 , C07D309/14 , C07H7/02 , C07K16/28 , C12N5/073
CPC classification number: C07H7/02 , C07D309/10 , C07D309/14 , C07K16/2875 , C07K2317/14 , C07K2317/41 , C12N5/0603 , C12N2501/999 , C12N2510/00
Abstract: Compounds of Formula (I) are useful as modulators of glycosylation. Compounds of Formula (I) have the following structure: (I) and the definitions of the other variables are provided herein.
Abstract translation: 式（I）的化合物可用作糖基化的调节剂。 式（I）的化合物具有以下结构：（I），本文提供其它变量的定义。
-
公开(公告)号：US20140148435A1
公开(公告)日：2014-05-29
申请号：US14170146
申请日：2014-01-31
Applicant: AMGEN INC.
Inventor： Jennifer R. Allen , Jian J. Chen , Michael J. Frohn , Matthew R. Kaller , Qingyian Liu , Thomas T. Nguyen , Alexander J. Pickrell , Wenyuan Qian , Robert M. Rzasa , Wenge Zhong
IPC: C07D471/04 , A61K31/517 , A61K45/06 , C07D403/14 , C07D401/14 , A61K31/497
CPC classification number: C07D471/04 , A61K31/497 , A61K31/517 , A61K45/06 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14
Abstract: Azetidine and piperidine compounds of formula (I): as defined in the specification, compositions containing them, and processes for preparing such compounds and intermediates thereof. Provided herein also are methods of treating cognitive disorders or diseases treatable by inhibition of PDE10, such as Huntington's Disease, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
Abstract translation: 式（I）的氮杂环丁烷和哌啶化合物：如说明书中所定义，含有它们的组合物，以及制备这些化合物的方法及其中间体。 本文还提供治疗认知障碍或通过抑制PDE10可治疗的疾病的方法，例如亨廷顿舞蹈病，精神分裂症，双相障碍，强迫症等。
-
公开(公告)号：US08691986B2
公开(公告)日：2014-04-08
申请号：US13917699
申请日：2013-06-14
Applicant: Amgen Inc.
Inventor： Jennifer R. Allen , Jian J. Chen , Michael J. Frohn , Matthew R. Kaller , Qingyian Liu , Thomas T. Nguyen , Alexander J. Pickrell , Wenyuan Qian , Robert M. Rzasa , Wenge Zhong
IPC: C07D241/00 , C07D239/70 , C07D471/02 , C07D215/00
CPC classification number: C07D471/04 , A61K31/497 , A61K31/517 , A61K45/06 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14
Abstract: Azetidine and piperidine compounds of formula (I): as defined in the specification, compositions containing them, and processes for preparing such compounds and intermediates thereof. Provided herein also are methods of treating cognitive disorders or diseases treatable by inhibition of PDE10, such as Huntington's Disease, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
Abstract translation: 式（I）的氮杂环丁烷和哌啶化合物：如说明书中所定义，含有它们的组合物，以及制备这些化合物的方法及其中间体。 本文还提供治疗认知障碍或通过抑制PDE10可治疗的疾病的方法，例如亨廷顿舞蹈病，精神分裂症，双相障碍，强迫症等。
-
公开(公告)号：US10941182B2
公开(公告)日：2021-03-09
申请号：US15317911
申请日：2015-06-10
Applicant: AMGEN INC.
Inventor： Jerry Ryan Holder , Gayathri Swaminath , Michael J. Frohn , Brian Alan Lanman , Anthony B. Reed , Leslie P. Miranda , John G. Allen , Alexander J. Pickrell , Aaron C. Siegmund , Lewis D. Pennington , Bryant Yang
Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
-
Patent Agency Ranking
公开(公告)号：US09174992B2
公开(公告)日：2015-11-03
申请号：US13780557
申请日：2013-02-28
Applicant: Amgen Inc.
Inventor： Jennifer R. Allen , Albert Amegadzie , Kristin L. Andrews , James Brown , Jian J. Chen , Ning Chen , Essa Hu Harrington , Qingyian Liu , Thomas T. Nguyen , Alexander J. Pickrell , Wenyuan Qian , Shannon Rumfelt , Robert M. Rzasa , Chester Chenguang Yuan , Wenge Zhong
IPC: C07D419/14 , C07D419/12 , C07D487/04 , C07D498/04 , C07D473/00 , C07D471/04 , C07D513/04 , C07D417/12 , C07D473/30 , C07D473/34 , C07D473/40 , C07D519/00
CPC classification number: C07D487/04 , C07D417/12 , C07D471/04 , C07D473/00 , C07D473/30 , C07D473/34 , C07D473/40 , C07D498/04 , C07D513/04 , C07D519/00
Abstract: Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.
Abstract translation: 式（I）的异双环化合物：或其药学上可接受的盐，互变异构体或立体异构体，以及含有它们的组合物，以及制备这些化合物的方法。 本文还提供治疗通过抑制PDE10可治疗的疾病或疾病的方法，例如肥胖症，非胰岛素依赖性糖尿病，精神分裂症，双相情感障碍，强迫症，亨廷顿舞蹈病等。
-
公开(公告)号：US20130338138A1
公开(公告)日：2013-12-19
申请号：US13917699
申请日：2013-06-14
Applicant: AMGEN INC.
Inventor： Jennifer R. Allen , Jian J. Chen , Michael J. Frohn , Matthew R. Kaller , Qingyian Liu , Thomas T. Nguyen , Alexander J. Pickrell , Wenyuan Qian , Robert M. Rzasa , Wenge Zhong
IPC: C07D401/14 , C07D471/04 , A61K31/517 , A61K31/497 , A61K45/06
CPC classification number: C07D471/04 , A61K31/497 , A61K31/517 , A61K45/06 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14
Abstract: Azetidine and piperidine compounds of formula (I): as defined in the specification, compositions containing them, and processes for preparing such compounds and intermediates thereof. Provided herein also are methods of treating cognitive disorders or diseases treatable by inhibition of PDE10, such as Huntington's Disease, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
Abstract translation: 式（I）的氮杂环丁烷和哌啶化合物：如说明书中所定义，含有它们的组合物，以及制备这些化合物的方法及其中间体。 本文还提供治疗认知障碍或通过抑制PDE10可治疗的疾病的方法，例如亨廷顿舞蹈病，精神分裂症，双相障碍，强迫症等。
-
公开(公告)号：US20180289720A1
公开(公告)日：2018-10-11
申请号：US15938001
申请日：2018-03-28
Applicant: AMGEN INC.
Inventor： Paul E. Harrington , Kate Ashton , Sean P. Brown , Matthew R. Kaller , Todd J. Kohn , Brian Alan Lanman , Kexue Li , Yunxiao Li , Jonathan D. Low , Ana Elena Minatti , Alexander J. Pickrell , Markian M. Stec , Joshua Taygerly
IPC: A61K31/553 , A61P35/00
CPC classification number: A61K31/553 , A61P35/00 , A61P35/02 , C07D498/08
Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
-
公开(公告)号：US09718803B2
公开(公告)日：2017-08-01
申请号：US14973491
申请日：2015-12-17
Applicant: AMGEN INC.
Inventor： Jennifer R. Allen , Jian J. Chen , Michael J. Frohn , Essa Hu Harrington , Qingyian Liu , Alexander J. Pickrell , Shannon Rumfelt , Robert M. Rzasa , Wenge Zhong
IPC: C07D401/14 , A61K31/497 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/08 , C07D487/04 , C07D491/08 , C07D487/08 , C07D487/10 , C07D491/107 , C07C53/18 , C07D491/056 , C07D513/04
CPC classification number: C07D401/14 , C07C53/18 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/056 , C07D491/08 , C07D491/107 , C07D513/04
Abstract: Unsaturated nitrogen heterocyclic compounds of formula (I): as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
-
公开(公告)号：US09493459B2
公开(公告)日：2016-11-15
申请号：US15058023
申请日：2016-03-01
Applicant: AMGEN INC.
Inventor： Jennifer R. Allen , Jian J. Chen , Michael J. Frohn , Matthew R. Kaller , Qingyian Liu , Thomas T. Nguyen , Alexander J. Pickrell , Wenyuan Qian , Robert M. Rzasa , Wenge Zhong
IPC: C07D401/04 , C07D403/04 , C07D471/04 , C07D401/14 , A61K31/497 , A61K45/06 , A61K31/517 , C07D403/14
CPC classification number: C07D471/04 , A61K31/497 , A61K31/517 , A61K45/06 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14
Abstract: Azetidine and piperidine compounds of formula (I): as defined in the specification, compositions containing them, and processes for preparing such compounds and intermediates thereof. Provided herein also are methods of treating cognitive disorders or diseases treatable by inhibition of PDE10, such as Huntington's Disease, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.025 seconds)
